ecancer
Avatar

ALPINE: A Randomized Phase 3 Study of Zanubrutinib vs. Ibrutinib for Treatment of R/R CLL and SLL

By ecancer FEATURING Jennifer Brown
By ecancer FEATURING Jennifer Brown
0 views
January 11, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Recommended

AUTOPLAY
12:47
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Feat. S. O'Brien, C. Coombs
17:05
Cleveland Clinic Taussig Cancer Institute

Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…

Feat. A. Winter
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
06:53
UC Irvine Health

Fixed-Duration Treatment in CLL: Current Considerations

Feat. E. Brem
25:47
Massachusetts General Hospital Cancer Center

Practice-Changing Updates in Indolent B-Cell Lymphomas

Feat. J. Soumerai
03:06
City of Hope

CLL Treatment Sequencing: The Importance of First Choice

Feat. S. Rosen
08:17
Adam Kittai

Highlights From iwCLL 2023: What's New and Practice Informing i…

06:56
Insights from 2023 ASH Annual Meeting

Efficacy of Ibrutinib Arms Across ALPINE and ELEVATE-RR Trials in R/…

Feat. M. Shadman
06:59
Constantine Tam

R/R CLL: A Matching-Adjusted Indirect Comparison of Zanubrutinib vs.…

15:21
5th SOHO Italy Annual Conference

How I Treat CLL at the MD Anderson Cancer Center

Feat. A. Ferrajoli
08:42
City of Hope

Venetoclax vs. BTKis in CLL Treatment

Feat. A. Danilov
08:45
Insights from 2023 ASH Annual Meeting

The Best of CLL: Highlights & Key Takeaways

Feat. V. Yazbeck
19:14
2024 ASCO® Annual Meeting Insights Hub

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…

Feat. K. Rogers, J. Woyach
10:06
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Results of A041702, an Alliance Phase 3 S…

Feat. J. Woyach
06:34
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "A Matching-Adjusted Indirect Comparison o…

Feat. A. Kittai
22:47
Indy Hematology Review

CLL: Evaluating and Therapeutic Approaches for the Management of the…

Feat. J. Woyach
10:19
Alvaro Alencar

Pirtobrutinib in R/R CLL

20:58
Andrew Lipsky

CLL: Recent Updates on the Use of BTK Inhibitors

06:21
City of Hope

Cardiac Safety of Zanubrutinib vs. Other BTKis in CLL

Feat. A. Danilov
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…